Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00637949 | Safety of Lumiracoxib in Patients With Osteoarthritis | PHASE3 | COMPLETED | 309 | — | — | Dec 1, 2000 | Mar 1, 2001 | Mar 18, 2008 | - | — |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| lumiracoxib | DEVICE | 400 mg once daily, oral over 6 weeks |
| rofecoxib | DRUG | 25 mg, oral, daily over 6 weeks |
Inclusion Criteria: * Age \>=50 years old * Primary osteoarthritis in hip, hand, knee or spine for at least 3 month * Pain in the target joint of moderate intensity * Written informed consent Exclusion Criteria: * Secondary osteoarthritis * Active upper gastro intestinal tract ulceration * Inflam...